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The peroxisome proliferator-activated receptors (PPARs) belong to a subclass of nuclear hormone receptor that executes important
cellular transcriptional functions. Previous studies have demonstrated the expression of PPARg in several tumours including colon,
breast, bladder, prostate, lung and stomach. This study demonstrates the relative expression of PPARg in normal ovaries and different
pathological grades of ovarian tumours of serous, mucinous, endometrioid, clear cell and mixed subtypes. A total of 56 ovarian
specimens including 10 normal, eight benign, 10 borderline, seven grade 1, nine grade 2 and 12 grade 3 were analysed using
immunohistochemistry. Immunoreactive PPARg was not expressed in normal ovaries. Out of eight benign and 10 borderline
tumours, only one tumour in each group showed weak cytoplasmic PPARg expression. In contrast, 26 out of 28 carcinomas studied
were positive for PPARg expression with staining confined to cytoplasmic and nuclear regions. An altered staining pattern of PPARg
was observed in high-grade ovarian tumours with PPARg being mostly localized in the nuclei with little cytoplasmic immunoreactivity.
On the other hand, predominant cytoplasmic staining was observed in lower-grade tumours. Significantly increased PPARg
immunoreactivity was observed in malignant ovarian tumours (grade 1, 2 and 3) compared to benign and borderline tumours
(w
2¼48.80, Po0.001). Western blot analyses showed significant elevation in the expression of immunoreactive PPARg in grade 3
ovarian tumours compared with that of normal ovaries and benign ovarian tumours (Po0.01). These findings suggest an involvement
of PPARg in the onset and development of ovarian carcinoma and provide an insight into the regulation of this molecule in the
progression of the disease.
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Epithelial ovarian cancer is the leading cause of death from
gynaecologic malignancies. As ovarian cancer produces few
specific symptoms in the early stage, most women present with
advanced stage disease where the prognosis is poor (Jacobs and
Menon, 2004). Greater than 90% of epithelial ovarian cancer arises
from the transformation of ovarian surface epithelium (Choi and
Auersperg, 2003). Hence, comparison between the protein expres-
sion profile of normal and transformed ovaries is important to
identify and understand the molecules involved in the onset and
progression of the disease.
The peroxisome proliferator-activated receptors (PPARs) com-
prise an important subfamily of the nuclear hormone receptor
superfamily. Three isoforms have been identified, PPARa, PPARb
and PPARg. Each exhibits distinct patterns of tissue distribution
and ligand specificity (Kersten et al, 2000). They share common
structural features, which include an amino-terminal modulatory
domain, a DNA-binding domain and a carboxyl-terminal ligand-
binding domain (Moras and Gronemeyer, 1998). PPARa is present
in high levels in the kidney, heart, muscle, liver, brown adipose
tissue and gut (Kliewer et al, 1994), whereas PPARb is ubiquitously
expressed throughout the body (Kliewer et al, 1994). PPARg is
highly expressed in adipose tissue, and is also present in other
tissues including the muscle, liver, heart, adrenal gland, spleen and
placenta (Asami-Miyagishi et al, 2004; Feingold et al, 2004).
The PPARs are ligand-dependent transcription factors that
regulate target gene expression by binding to specific peroxisome
proliferator response elements (PPREs) in enhancer sites of target
genes (Berger and Moller, 2002). Each receptor binds its PPREs as
a heterodimer with a retinoid X receptor. Upon ligand activation,
conformational rearrangement of PPARg expresses transcriptional
coactivator binding sites. Recruitment of coactivators involves
transcription of genes implicated in the regulation of cell
differentiation and activation pathways (Berger and Moller, 2002).
In cancer biology, PPARg is the most intensively studied PPAR
isoform. It is expressed in high levels in different cancer including
colon (Bull, 2003), breast (Jiang et al, 2003), bladder (Yoshimura
et al, 2003), prostate (Smith and Kantoff, 2002), head and neck
(Jaeckel et al, 2001), cervical (Han et al, 2003) and endometrial
cancer (Tong et al, 2000). Recent studies have demonstrated that
ligand activation of PPARg receptor is involved in adipocyte (Seo
et al, 2004) and tumour cell differentiation (Gauthier et al, 2003).
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sIn colon cancer, ligand activation of PPARg-mediated differentia-
tion of certain colon cancer cells results in the upregulation of
tumour suppressor genes caveolin 1 and 2 (Burgermeister et al,
2003) and repression of cyclin D1 expression (Wang et al, 2003).
Similarly, in vitro studies in prostate cancer cells, which express
fairly abundant PPARg, can result in the differentiation of prostate
cancer cells and downregulation of androgen-stimulated PSA
production (Hisatake et al, 2000). These findings have potentially
important functional implication in the context of cancer cell
differentiation therapy and multidrug resistance. Recently, Her2
has been shown to regulate PPAR expression (Yang et al, 2003).
The ligands for PPARg have been shown to increase the expression
of BRCA 1 protein in human breast cancer cells (Pignatelli et al,
2003), indicating that PPARg plays a crucial role in BRCA1
regulatory pathways involved in the pathogenesis of breast and
sporadic ovarian cancer.
To our knowledge, a role for PPARg in ovarian cancer
development or function has not been described. In this study,
we evaluated immunoreactive PPARg protein expression in
different pathological grades and subtypes of human epithelial
ovarian tumours. We show that ovarian tumours express PPARg
and that expression is significantly higher in malignant tumours
compared to benign tumours and normal ovaries. We also
demonstrate that PPARg expression pattern alters in high-grade
ovarian tumours, implicating an important role for PPARg in the
progression of ovarian malignancy.
MATERIALS AND METHODS
Antibody and reagents
Mouse monoclonal and rabbit polyclonal antibodies against
PPARg were obtained from Santa Cruz Biotechnology Inc. (Santa
Cruz, CA, USA). Mouse IgG1 was obtained from Sigma (Sigma, St
Louis, MO, USA). Immunoperoxidase secondary detection system
was obtained from Chemicon International (Temecula, USA). ECL
Western blotting detection reagents and analysis system were
supplied by Amersham Biosciences (Amersham, UK).
Immunohistochemistry
The study was approved by the Research and Human Ethics
Committee (HEC#02/30) of the Royal Women’s Hospital, Mel-
bourne, Australia. Human ovarian tumour tissues were collected at
the time of surgical cytoreduction with the informed consent of the
patients. Patient information is presented in Table 1. Normal
ovaries for control comparison were collected from patients
undergoing surgery as a result of suspicious ultrasound, from
prophylactic oophorectomy specimens. The pathology diagnosis
and tumour grade was evaluated by two staff pathologists in the
Department of Pathology, the Royal Women’s Hospital, Mel-
bourne, Australia. The classification of the tumours was performed
as part of the clinical diagnosis according to the method described
by Silverberg (2000). Surgically removed samples were fixed in
10% formalin and embedded in paraffin. Tissues for Western blot
were snap frozen in liquid nitrogen and stored at  801C until
needed.
Paraffin-embedded ovarian tissues were cut at 4mm thickness
and deparaffinised with xylene and rehydrated using graded
ethanol. After microwave antigen retrieval in citrate buffer, pH 6.0,
the sections were held in Tris buffer solution (TBS, 100mM,p H
7.6). Endogenous peroxidase activity was inactivated using 3%
hydrogen peroxide in methanol and endogenous biotin activity
was blocked by a sequence of diluted egg white (5% in distilled
water) and skimmed milk powder (5% in distilled water), all for
10min each. The sections were incubated in mouse monoclonal
antibody against PPARg (1/400 in 1% BSA in TBS) overnight at
41C. Antibody binding was amplified using biotin and streptavidin
HRP for 10min each and the complex was visualised using
diaminobenzidine. The nuclei were lightly stained with Mayer’s
haematoxylin and the sections were mounted and cover slipped.
An isotype IgG1 matched diluted was substituted for the antibody
as negative control.
Sections were assessed microscopically for positive staining by
two experienced observers. For each specimen, the positive
staining extent was scored as five grades, namely, 0 (p10%), 1
(X11–25%), 2 (X26–50%), 3 (X51–75%), 4(X76–90%) and 5
(X91–100%) (Armes et al, 1999). The intensity was classified into
four grades: no staining, negative ( ); pale brown, weak (þ);
brown, moderate (þþ) and dark brown, strong (þþþ).
Parallel paraffin-embedded sections were stained with haematox-
ylin and eosin to confirm the pathologic diagnosis simultaneously.
Western blot
Preparation of ovarian tissue homogenate was performed as
described previously (Ahmed et al, 2004). Each frozen ovarian
specimen (100mg) was cut into several small pieces about 3mm in
size. Then, the specimen was homogenized in Tris-HCl buffer
(10mM Tris, 150mM NaCl, 2mM EDTA, 2mM dithiothreitol, 1mM
orthovanadate, 1mM phenylmethylsulphonyl fluoride, 5mgml
 1
aprotonin, pH 7.0) by repeated uniform strokes (approximately 6).
The samples were centrifuged at 10000g for 20min. The super-
natant was collected and relative protein concentration was
determined using Bio-Rad Protein Assay Reagent following the
manufacturer’s instruction. Ovarian homogenate containing equal
amounts (10mg) of protein were separated by electrophoresis on
10% sodium dodecyl sulphate (SDS)–polyacrylamide gels under
nonreducing condition and transferred to nitrocellulose mem-
branes. The membranes were probed with rabbit polyclonal anti-
PPARg (diluted 1:400 in 3% skim milk in TBST) followed by
Table 1 Description of ovarian cancer patients participating in the study
Case no.
Histological
grade
Clinical
stage
Tumour
subtype
CA125
(Uml
 1)
6 1 1a Endometrioid 773
64 1 1b Endometrioid 786
83 1 1c Endometrioid 126
106 1 3c Mixed 93
164 1 1b Endometrioid 636
190 1 1a Mucinous 25
198 1 2c Endometrioid 55
32 2 1a Endometrioid 302
35 2 3c Serous 1200
46 2 4 Serous 3457
49 2 3c Serous 900
110 2 3c Serous 1719
121 2 3c Serous 3471
123 2 3b Mixed 106
129 2 3c Mixed 3823
161 2 1c Mixed 698
2 3 3c Serous 647
3 3 3c Serous 513
44 3 2b Endometrioid 165
85 3 1a Serous 147
88 3 3c Serous 883
90 3 3c Endometrioid 659
96 3 3c Serous 137
108 3 3c Serous 61
143 3 4 Clear cell 507
146 3 4 Serous 2463
153 3 4 Serous 985
158 3 3c Serous 287
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speroxidase-labelled donkey anti-rabbit secondary antibody
(1:2500) and visualised by the ECL (Amersham, UK) detection
system according to the manufacturer’s instruction.
Statistical analysis
The extent and intensity of immunohistochemical staining
between benign, borderline and high-grade ovarian tumours was
determined by w
2 test. The association between the optical density
(OD) of PPARg bands determined by Western blotting in benign
tumours compared to that of high-grade ovarian tumours was
assessed by Student’s t-test.
RESULTS
Immunohistochemical staining of PPARc in ovarian
tumour tissues
Immunohistochemical expression of PPARg in epithelial ovarian
tumours is described in Table 2. No immunoreactivity of PPARg
was observed in normal ovarian tissues (Figure 1C). Among eight
benign and 10 borderline ovarian tumours, weak PPARg expres-
sion was present in only one tumour in each group (Figure 2A).
Seven cases of grade 1 ovarian tumours were studied. Four of these
showed weak staining and moderate staining was observed in three
cases. Both cytoplasmic and nuclear staining was observed
(Figure 2B), the distribution being approximately 60% cytoplasmic
and 40% nuclear.
Eight out of nine grade 2 tumours studied were positive for
PPARg and the expression varied from a score of 1 to 3 with
increased demonstration of nuclear staining (Figure 2C). Nuclear
staining of infiltrating macrophages was observed in one case. In
all, 12 grade 3 ovarian tumours were studied and 11 of these were
positive. The intensity of PPARg staining varied but was
predominantly judged to be moderate (þþ) (Figures 1D and
2D, E). In grade 2 and 3 tumours, staining was predominantly
nuclear. Cytoplasmic staining in higher grades (grades 2 and 3)
represented approximately 20% of total staining.
Overall, the immunoreactive PPARg was present in all grades of
ovarian tumours. The extent of overall staining was significantly
higher in malignant ovarian tumours (grades 1, 2 and 3) compared
with benign and borderline tumours (w
2¼48.80, Po0.001)
(Table 2). PPARg staining in ovarian tumours was mainly localised
to the cytoplasm or nuclei of tumour cells. Nuclear staining
Table 2 Extent and intensity of PPARg expression in normal ovaries and
tumour tissues
Histology
Total
number of
tissues
Extent of staining
(number of
tissues)
Intensity of
staining (number
of tissues)
Normal 10 0 (10)   (10)
Benign 8 0 (7), 1 (1)   (7), + (1)
Borderline 10 0 (9), 1 (1)   (9), + (1)
Grade 1 7 0 (0), 1 (6), 2 (0), 3 (1)   (0), + (3), ++ (4)
Grade 2 9 0 (1), 1 (5), 2 (1), 3 (2)   (1), + (5), ++ (3)
Grade 3 12 0 (1), 1 (5), 2 (1), 3 (5)   (1), + (7), ++ (4)
Total 56 56 56
PPAR¼peroxisome proliferator-activated receptor. Extent of PPARg expression
was scored as 0 (p10%), 1 (X11–25%), 2 (X26–50%), 3 (X51–75%), 4(X76–
90%) and 5 (X91–100%) immunoreactivity. Values within parentheses indicate
number of tissues in each category. The extent of staining was significantly different in
grade 1, 2 and 3 tumours compared to benign and borderline tumours (w
2¼48.80;
Po0.001). The intensity of staining was scored as negative ( ), weak (+), moderate
(++) and strong (+++) staining. The values within parentheses indicate the number
of tissues in each category. The intensity of staining was significantly different in grade
1, 2 and 3 tumours compared to benign and borderline tumours (w
2¼43.93;
Po0.001).
Figure 1 (A and B) Haematoxylin and eosin staining of (A) normal ovary, (B) grade 3 serous tumour. PPARg staining of the same (C) normal ovary (D)
and grade 3 serous ovary. Blue arrows indicate nuclear PPARg staining, while black indicates cytoplasmic staining.
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sincreased significantly with the grade of the tumours (80% in grade
3 compared to 40% in grade 1). Tumour stroma or endothelial cells
lining the blood vessels were negative for PPARg immunoreactiv-
ity. The intensity of PPARg staining was also significantly higher in
malignant tumours compared with benign and borderline tumours
(w
2¼43.93, Po0.001) (Table 2). No statistical difference in the
extent or intensity of staining was observed between the different
grades of tumours (grades 1, 2 and 3) (w
2¼4.29, P¼0.6363;
w
2¼1.68, P¼0.79) (Table 2).
Expression of PPARc in ovarian tumour tissues using
Western blot analysis
The expression of PPARg in human ovarian tumour tissues was
also evaluated by Western blot analyses (Figure 3). The expression
of PPARg in ovarian tumour tissues was significantly higher than
in normal ovaries and benign ovarian tumours (Po0.01)
(Figure 3A). However, no difference in the expression of PPARg
in normal ovaries and benign ovarian tumours was demonstrated
(P40.05) (Figure 3C).
DISCUSSION
The sustainability of a malignant tumour requires multiple cellular
events by which the cancer cells acquire growth factor indepen-
dence, escape cellular apoptosis mechanisms, create a self-
sustaining environment and escape the neighbouring barriers by
migrating and colonising to a distant site (Hanahan and Weinberg,
2000). These events require the expression/overexpression and
activation of molecules not generally requisite for normal cellular
functions. The initial indication that the PPARs are involved in the
aetiology of cancer was the isolation of PPARa as the mediator of
the tumour-promoting effect of peroxisome proliferators, com-
pounds that cause heptocellular carcinoma in rodents (Corton et al,
2000). PPARa has been shown to be expressed in colon tumours
and overexpressed in breast and prostate tumours (Collett et al,
2000; Roberts-Thomson and Snyderwine, 2000). PPARb levels are
also elevated in colon and head and neck cancer (Gupta et al, 2000;
Jaeckel et al, 2001) and the absence of PPARb reduces tumour
growth in colon cancer (Park et al, 2001). Although PPARg is
expressed at low levels in normal colonic and breast ductal
epithelium, it is significantly increased in breast and prostate
Figure 2 PPARg staining of (A) benign mucinous tumour, (B) grade 1 mucinous tumour, (C) grade 2 endometrioid tumour, (D) grade 3 endometrioid
tumours and (E) grade 3 serous tumour. Arrows indicate nuclear (blue) and cytoplasmic (black) PPARg staining.
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scarcinoma. The expression of this receptor has not been reported
in ovarian carcinoma but has been shown in normal ovaries
(Lambe and Tugwood, 1996). In this study, we report the
expression of PPARg in different pathological grades and subtypes
of ovarian carcinoma and discuss its possible function with the
progression of the disease.
We report for the first time that ovarian tumours express
PPARg. Weak to moderate expression of PPARg by immunohis-
tochemistry was observed in almost all ovarian tumours studied.
As shown in Table 2 and Figure 1, immunohistochemical staining
showed no PPARg expression in normal ovarian tissues. Out of
eight benign and 10 borderline tumours, only one in each group
stained positive for PPARg expression. Weak to moderate staining
was observed in grade 1 ovarian tumours (Figure 2B), and the
staining was localised to both cytoplasmic and nuclear areas of the
cells. Compared to benign and borderline tumours, the extent of
staining was, however, significantly increased in grade 3 ovarian
tumours, with immunoreactivity for PPARg being mostly present
in the nuclear region (Figures 1 and 2). Western blotting analyses
demonstrated significant enhancement in the expression of PPARg
in grade 3 ovarian tumours compared to benign ovarian tumours
and normal ovaries (Figure 3). The basal expression of PPARg in
normal ovarian tissues and benign ovarian tumours may have
been attributed by the increased immunosensitivity of Western
blotting technique compared to immunohistochemistry.
The results from our study are consistent with those of other
studies performed in other cancers. Very weak immunohisto-
chemical staining of PPARg was shown in benign prostatic
hyperplasia and normal prostate tissues, whereas significant
enhancement in the expression of immunoreactive PPARg was
observed in malignant prostate tissues (Park et al, 2001). PPARg
expression was shown to be higher in high-grade bladder cancer
compared to low-grade cancer (Yoshimura et al, 2003). Irrespec-
tive of the differentiation status of the tumour, strong expression
of immunoreactive PPARg was observed in surgically resected
human gastric cancer tissues (Sato et al, 2000).
In contrast, in some cases of cancer, the expression of PPARg
decreases with the histological grade of the tumour. In full-term
normal placenta, PPARg is strongly expressed in the nuclei of the
syncytiotrophoblast, extravillous cytotrophoblast of cell islands
and cell columns, whereas in choriocarcinoma, only a few
trophoblastic cells show weak staining for PPARg (Capparuccia
et al, 2002). Well-differentiated lung adenocarcinomas present
increased frequency for PPARg expression compared with
moderately and poorly differentiated ones (Theocharis et al,
2002). The expression of PPARg protein is decreased in
oesophageal cancer tissues compared with normal oesophageal
squamous epithelium (Terashita et al, 2002). Hence, considering
the diversity of human cancer, the expression of PPARg is possibly
dependent on tissue specificity and/or the mutational events (as in
the case of colon cancer) (Ikezoe et al, 2001) that are requisite for
cancer development.
The growth inhibitory and differentiation roles of PPARg have
been shown in several cancers (Demetri et al, 1999). The
immunohistochemical expression of PPARg during the progres-
sion of ovarian cancer can be related to the growth-promoting role
of PPARg previously shown in certain cancer (Mueller et al, 2000).
In the case of thyroid follicular cancer, a chromosomal transloca-
tion and fusion of PAX8 gene with PPARg results in a malignant
phenotype, suggesting a link of PPARg to cancer growth (Dwight
et al, 2003). In the Min mouse model of APC deficiency, ligands for
PPARg can increase colon tumour growth (Lefebvre et al, 1998). In
another study, loss of PPARg was shown not to affect mammary
development and propensity for tumour formation but resulted in
reduced fertility (Cui et al, 2002). Overall, ligand activation of
PPARg in tumour models can result in diversified functional
outcome (Leung et al, 2004) and a better understanding of the
exact role of PPARg in cancer needs to be determined. In
particular, the mechanism of differentiation of cancers is
incompletely understood and an insight into this process would
undoubtedly lead to new therapeutic targets.
The anti-inflammatory response of PPARg in association with
NF-kB has recently been identified (Kelly et al, 2004). In addition,
PPARg ligands have been shown to inhibit transcriptional
activation of COX-2 in human epithelial cells (Badawi et al,
2004). In certain cancer cells, ligand activation of PPARg results in
the inhibition of the release of inflammatory cytokines by cancer
cells (Leung et al, 2004). These results may help to explain the
shuttling of PPARg expression from the cytoplasm to nucleus with
the progression of ovarian carcinoma. As ovarian cancer
progresses, tumour cells are more likely to be exposed to
inflammatory cytokines secreted by cancer cells themselves and
infiltrating leucocytes present in the peritoneum. Whether this
increased exposure of ovarian tumour cells to the inflammatory
cytokines result in the activation of PPARg and subsequent
cytoplasmic translocation to the nucleus is yet to be determined.
Taken together, our results indicate that PPARg may play a role
in the onset and progression of ovarian cancer. Further research
need to investigate the prognostic significance of PPARg expres-
sion in ovarian carcinoma and whether therapeutic administration
of ligands for this receptor may have clinical potential for the
treatment of the disease.
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Figure 3 Western blot analyses of PPARg expression in normal ovary,
benign and grade 3 ovarian tumours. (A) Western blot was carried out as
described in the Material and Methods section. A total of 10mg of protein
was loaded in a total volume of 20ml in each lane. The results are
representative of one experiment repeated three times. (B) b-actin staining
of the same samples loaded in same concentration to ensure equal protein
loading. (C) Quantification of PPARg expression was performed by
densitometry and expressed as mean peak OD7s.e.m. of the number of
samples described in each group.
Expression of PPARc in human ovarian cancer
GY Zhang et al
117
British Journal of Cancer (2005) 92(1), 113–119 & 2005 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sREFERENCES
Ahmed N, Oliva K, Rice GE, Quinn MA (2004) Cell-free 59kDa
immunoreactive integrin-linked kinase: a novel marker for ovarian
carcinoma. Clin Cancer Res 10: 2415–2420
Armes JE, Trute L, White D, Southey MC, Hammet F, Tesoriero A,
Hutchins AM, Dite GS, McCredie MR, Giles GG, Hopper JL, Venter DJ
(1999) Distinct molecular pathogeneses of early-onset breast cancers in
BRCA1 and BRCA2 mutation carriers: a population-based study. Cancer
Res 59: 2011–2017
Asami-Miyagishi R, Iseki S, Usui M, Uchida K, Kubo H, Morita I (2004)
Expression and function of PPARgamma in rat placental development.
Biochem Biophys Res Commun 315: 497–501
Badawi AF, Eldeen MB, Liu Y, Ross EA, Badr MZ (2004) Inhibition of rat
mammary gland carcinogenesis by simultaneous targeting of cycloox-
ygenase-2 and peroxisome proliferator-activated receptor gamma.
Cancer Res 64: 1181–1189
Berger J, Moller DE (2002) The mechanisms of action of PPARs. Annu Rev
Med 53: 409–435
Bull AW (2003) The role of peroxisome proliferator-activated receptor
gamma in colon cancer and inflammatory bowel disease. Arch Pathol Lab
Med 127: 1121–1123
Burgermeister E, Tencer L, Liscovitch M (2003) Peroxisome proliferator-
activated receptor-gamma upregulates caveolin-1 and caveolin-2 expres-
sion in human carcinoma cells. Oncogene 22: 3888–3900
Capparuccia L, Marzioni D, Giordano A, Fazioli F, De Nictolis M, Busso N,
Todros T, Castellucci M (2002) PPARgamma expression in normal
human placenta, hydatidiform mole and choriocarcinoma. Mol Hum
Reprod 8: 574–579
Choi KC, Auersperg N (2003) The ovarian surface epithelium: simple
source of a complex disease. Minerva Ginecol 55: 297–314
Collett GP, Betts AM, Johnson MI, Pulimood AB, Cook S, Neal DE, Robson
CN (2000) Peroxisome proliferator-activated receptor alpha is an
androgen-responsive gene in human prostate and is highly expressed
in prostatic adenocarcinoma. Clin Cancer Res 6: 3241–3248
Corton JC, Lapinskas PJ, Gonzalez FJ (2000) Central role of PPARalpha in
the mechanism of action of hepatocarcinogenic peroxisome prolifera-
tors. Mutat Res 448: 139–151
Cui Y, Miyoshi K, Claudio E, Siebenlist UK, Gonzalez FJ, Flaws J, Wagner
KU, Hennighausen L (2002) Loss of the peroxisome proliferation-
activated receptor gamma (PPARgamma) does not affect mammary
development and propensity for tumor formation but leads to reduced
fertility. J Biol Chem 277: 17830–17835, Epub 2002 Mar 7
Demetri GD, Fletcher CD, Mueller E, Sarraf P, Naujoks R, Campbell N,
Spiegelman BM, Singer S (1999) Induction of solid tumor differentiation
by the peroxisome proliferator-activated receptor-gamma ligand trogli-
tazone in patients with liposarcoma. Proc Natl Acad Sci USA 96:
3951–3956
Dwight T, Thoppe SR, Foukakis T, Lui WO, Wallin G, Hoog A, Frisk T,
Larsson C, Zedenius J (2003) Involvement of the PAX8/peroxisome
proliferator-activated receptor gamma rearrangement in follicular
thyroid tumors. J Clin Endocrinol Metab 88: 4440–4445
Feingold K, Kim MS, Shigenaga J, Moser A, Grunfeld C (2004) Altered
expression of nuclear hormone receptors and coactivators in mouse
heart during the acute-phase response. Am J Physiol Endocrinol Metab
286: E201–E207
Gauthier A, Vassiliou G, Benoist F, McPherson R (2003) Adipocyte low
density lipoprotein receptor-related protein gene expression and
function is regulated by peroxisome proliferator-activated receptor
gamma. J Biol Chem 278: 11945–11953, Epub 2003 Jan 27
Gupta RA, Tan J, Krause WF, Geraci MW, Willson TM, Dey SK, DuBois RN
(2000) Prostacyclin-mediated activation of peroxisome proliferator-
activated receptor delta in colorectal cancer. Proc Natl Acad Sci USA
97: 13275–13280
Han S, Inoue H, Flowers LC, Sidell N (2003) Control of COX-2 gene
expression through peroxisome proliferator-activated receptor gamma in
human cervical cancer cells. Clin Cancer Res 9: 4627–4635
Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:
57–70
Hisatake JI, Ikezoe T, Carey M, Holden S, Tomoyasu S, Koeffler HP (2000)
Down-regulation of prostate-specific antigen expression by ligands for
peroxisome proliferator-activated receptor gamma in human prostate
cancer. Cancer Res 60: 5494–5498
Ikezoe T, Miller CW, Kawano S, Heaney A, Williamson EA, Hisatake J,
Green E, Hofmann W, Taguchi H, Koeffler HP (2001) Mutational analysis
of the peroxisome proliferator-activated receptor gamma gene in human
malignancies. Cancer Res 61: 5307–5310
Jacobs IJ, Menon U (2004) Progress and challenges in screening for early
detection of ovarian cancer. Mol Cell Proteomics 3: 355–366, Epub 2004
Feb 5
Jaeckel EC, Raja S, Tan J, Das SK, Dey SK, Girod DA, Tsue TT, Sanford TR
(2001) Correlation of expression of cyclooxygenase-2, vascular endothe-
lial growth factor, and peroxisome proliferator-activated receptor delta
with head and neck squamous cell carcinoma. Arch Otolaryngol Head
Neck Surg 127: 1253–1259
Jiang WG, Douglas-Jones A, Mansel RE (2003) Expression of peroxisome-
proliferator activated receptor-gamma (PPARgamma) and the PPAR-
gamma co-activator, PGC-1, in human breast cancer correlates with
clinical outcomes. Int J Cancer 106: 752–757
Kelly D, Campbell JI, King TP, Grant G, Jansson EA, Coutts AG, Pettersson
S, Conway S (2004) Commensal anaerobic gut bacteria attenuate
inflammation by regulating nuclear-cytoplasmic shuttling of PPAR-
gamma and RelA. Nat Immunol 5: 104–112, Epub 2003 Dec 21
Kersten S, Desvergne B, Wahli W (2000) Roles of PPARs in health and
disease. Nature 405: 421–424
Kliewer SA, Forman BM, Blumberg B, Ong ES, Borgmeyer U, Mangelsdorf
DJ, Umesono K, Evans RM (1994) Differential expression and activation
of a family of murine peroxisome proliferator-activated receptors. Proc
Natl Acad Sci USA 91: 7355–7359
Lambe KG, Tugwood JD (1996) A human peroxisome-proliferator-activated
receptor-gamma is activated by inducers of adipogenesis, including
thiazolidinedione drugs. Eur J Biochem. 239: 1–7
Lefebvre AM, Chen I, Desreumaux P, Najib J, Fruchart JC, Geboes K, Briggs
M, Heyman R, Auwerx J (1998) Activation of the peroxisome
proliferator-activated receptor gamma promotes the development of
colon tumors in C57BL/6J-APCMin/+ mice. Nat Med 4: 1053–1057
Leung WK, Bai AH, Chan VY, Yu J, Chan MW, To KF, Wu JR, Chan KK, Fu
YG, Chan FK, Sung JJ (2004) Effect of peroxisome proliferator activated
receptor gamma ligands on growth and gene expression profiles of
gastric cancer cells. Gut 53: 331–338
Moras D, Gronemeyer H (1998) The nuclear receptor ligand-binding
domain: structure and function. Curr Opin Cell Biol 10: 384–391
Mueller E, Smith M, Sarraf P, Kroll T, Aiyer A, Kaufman DS, Oh W, Demetri
G, Figg WD, Zhou XP, Eng C, Spiegelman BM, Kantoff PW (2000) Effects
of ligand activation of peroxisome proliferator-activated receptor gamma
in human prostate cancer. Proc Natl Acad Sci USA 97: 10990–10995
Park BH, Vogelstein B, Kinzler KW (2001) Genetic disruption of PPARdelta
decreases the tumorigenicity of human colon cancer cells. Proc Natl Acad
Sci USA 98: 2598–2603
Pignatelli M, Cocca C, Santos A, Perez-Castillo A, Jiang WG, Douglas-Jones
A, Mansel RE (2003) Enhancement of BRCA1 gene expression by the
peroxisome proliferator-activated receptor gamma in the MCF-7 breast
cancer cell line. Oncogene 22: 5446–5450
Roberts-Thomson SJ, Snyderwine EG (2000) Characterization of peroxi-
some proliferator-activated receptor alpha in normal rat mammary gland
and 2-amino-l-methyl-6-phenylimidazo[4, 5-b]pyridine-induced mam-
mary gland tumors from rats fed high and low fat diets. Toxicol Lett 118:
79–86
Sato H, Ishihara S, Kawashima K, Moriyama N, Suetsugu H, Kazumori H,
Okuyama T, Rumi MA, Fukuda R, Nagasue N, Kinoshita Y (2000)
Expression of peroxisome proliferator-activated receptor (PPAR)gamma
in gastric cancer and inhibitory effects of PPARgamma agonists. Br J
Cancer 83: 1394–1400
Seo JB, Moon HM, Kim WS, Lee YS, Jeong HW, Yoo EJ, Ham J, Kang H,
Park MG, Steffensen KR, Stulnig TM, Gustafsson JA, Park SD, Kim JB
(2004) Activated liver X receptors stimulate adipocyte differentiation
through induction of peroxisome proliferator-activated receptor gamma
expression. Mol Cell Biol 24: 3430–3444
Silverberg S (2000) Histopathologic grading of ovarian carcinoma: a review
an proposal. Int J Gynecol Pathol 19: 7–15
Smith MR, Kantoff PW (2002) Peroxisome proliferator-activated receptor
gamma (PPargamma) as a novel target for prostate cancer. Invest New
Drugs 20: 195–200
Terashita Y, Sasaki H, Haruki N, Nishiwaki T, Ishiguro H, Shibata Y, Kudo
J, Konishi S, Kato J, Koyama H, Kimura M, Sato A, Shinoda N, Kuwabara
Y, Fujii Y (2002) Decreased peroxisome proliferator-activated receptor
gamma gene expression is correlated with poor prognosis in patients
with esophageal cancer. Jpn J Clin Oncol 32: 238–243
Expression of PPARc in human ovarian cancer
GY Zhang et al
118
British Journal of Cancer (2005) 92(1), 113–119 & 2005 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sTheocharis S, Kanelli H, Politi E, Margeli A, Karkandaris C, Philippides T,
Koutselinis A (2002) Expression of peroxisome proliferator activated
receptor-gamma in non-small cell lung carcinoma: correlation with
histological type and grade. Lung Cancer 36: 249–255
Tong BJ, Tan J, Tajeda L, Das SK, Chapman JA, DuBois RN, Dey SK (2000)
Heightened expression of cyclooxygenase-2 and peroxisome proliferator-
activated receptor-delta in human endometrial adenocarcinoma. Neo-
plasia 2: 483–490
Wang C, Pattabiraman N, Zhou JN, Fu M, Sakamaki T, Albanese C, Li Z,
Wu K, Hulit J, Neumeister P, Novikoff PM, Brownlee M, Scherer PE,
Jones JG, Whitney KD, Donehower LA, Harris EL, Rohan T, Johns DC,
Pestell RG, Jiang WG, Douglas-Jones A, Mansel RE (2003) Cyclin D1
repression of peroxisome proliferator-activated receptor gamma expres-
sion and transactivation. Mol Cell Biol 23: 6159–6173
Yang Z, Bagheri-Yarmand R, Balasenthil S, Hortobagyi G, Sahin AA, Barnes
CJ, Kumar R (2003) HER2 regulation of peroxisome proliferator-
activated receptor gamma (PPARgamma) expression and sensitivity of
breast cancer cells to PPARgamma ligand therapy. Clin Cancer Res 9:
3198–3203
Yoshimura R, Matsuyama M, Segawa Y, Hase T, Mitsuhashi M, Tsuchida K,
Wada S, Kawahito Y, Sano H, Nakatani T (2003) Expression of
peroxisome proliferator-activated receptors (PPARs) in human urinary
bladder carcinoma and growth inhibition by its agonists. Int J Cancer
104: 597–602
Expression of PPARc in human ovarian cancer
GY Zhang et al
119
British Journal of Cancer (2005) 92(1), 113–119 & 2005 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
s